DLD Asset Management’s aTyr Pharma ATYR Stock Holding History

DLD Asset Management’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-309,800	Closed	-$223K	–	481
2025 Q3	$223K	Buy	+309,800	New	+$1.4M	0.02%	254

Other funds holding ATYR

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DLD Asset Management's ATYR Position: Q4 2025 in Review

DLD Asset Management sold out of aTyr Pharma (ATYR) in Q4 2025, closing a stake of 40,000 shares — an estimated $28.9K sold.

DLD Asset Management first reported a position in ATYR in Q3 2025 and held it in 1 quarter. The position peaked at $28.9K in Q3 2025. 84 funds tracked by Wall St. Rank hold ATYR as of Q4 2025.

DLD Asset Management reported no remaining aTyr Pharma position as of Q4 2025 after selling out during the quarter.
DLD Asset Management sold 40,000 aTyr Pharma shares in Q4 2025, an estimated $28.9K.
DLD Asset Management first reported a position in aTyr Pharma in Q3 2025 and held it in 1 quarter.
DLD Asset Management's aTyr Pharma position peaked at $28.9K in Q3 2025.
84 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2025.

Based on DLD Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.